Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes
Graefe's Archive for Clinical and Experimental Ophthalmology · 2024
DOI: 10.1007/s00417-024-06531-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, 2024. Verfasst von Hansjürgen Agostini und 17 weiteren Autor:innen. Beteiligte Einrichtung: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Macular Edema. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche.
Abstract (Originalsprache)
Intravitreal anti–vascular endothelial growth factor (VEGF) therapy is the standard of care for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD); however, vision gains and anatomical improvements are not sustained over longer periods of treatment, suggesting other relevant targets may be needed to optimize treatments. Additionally, frequent intravitreal injections can prove a burden for patients and caregivers. Angiopoietin-2 (Ang-2) has been explored as an additional therapeutic target, due to the involvement of Ang-2 in DME and nAMD pathogenesis. Recent evidence supports the hypothesis that targeting both VEGF and Ang-2 may improve clinical outcomes in DME and nAMD compared with targeting VEGF alone by enhancing vascular stability, resulting in reduced macular leakage, prevention of neovascularization, and diminished inflammation. Faricimab, a novel bispecific antibody that targets VEGF-A and Ang-2, has been evaluated in clinical trials for DME (YOSEMITE/RHINE) and nAMD (TENAYA/LUCERNE). These trials evaluated faricimab against the anti-VEGFA/B and anti–placental growth factor fusion protein aflibercept, both administered by intravitreal injection. In addition to faricimab efficacy, safety, and pharmacokinetics, durability was evaluated during the trials using a treat-and-extend regimen. At 1 year, faricimab demonstrated non-inferior vision gains versus aflibercept across YOSEMITE/RHINE and TENAYA/LUCERNE. In YOSEMITE/RHINE, faricimab improved anatomic parameters versus aflibercept. Reduction of central subfield thickness (CST), and absence of both DME and intraretinal fluid were greater in faricimab- versus aflibercept-treated eyes. In TENAYA/LUCERNE, CST reductions were greater for faricimab than aflibercept at the end of the head-to-head phase (0–12 weeks), and were comparable with aflibercept at year 1, but with less frequent dosing. CST and vision gains were maintained during year 2 of both YOSEMITE/RHINE and TENAYA/LUCERNE. These findings suggest that dual Ang-2/VEGF-A pathway inhibition may result in greater disease control versus anti-VEGF alone, potentially addressing the unmet needs and reducing treatment burden, and improving real-world outcomes and compliance in retinal vascular diseases. Long-term extension studies (RHONE-X, AVONELLE-X) are ongoing. Current evidence suggests that dual inhibition with faricimab heralds the beginning of multitargeted treatment strategies inhibiting multiple, independent components of retinal pathology, with faricimab providing opportunities to reduce treatment burden and improve outcomes compared with anti-VEGF monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Genentech, Inc., South San Francisco, CA, USA.
- Tufts Medicine New England Eye Center, Boston, MA, USA.
- Apellis Pharmaceuticals, Waltham, MA, USA.
- Retina Foundation of the Southwest, Dallas, TX, USA.
- Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA.
Förderung
- Roche
Zitieren
APA
Agostini, H., Abreu, F., Baumal, C. R., Chang, D. S., G Csaky, K., Demetriades, A. M., Kodjikian, L., Lim, J. I., Margaron, P., Monés, J. M., Peto, T., Ricci, F., Rüth, M., Singh, R. P., Stoilov, I., Swaminathan, B., Willis, J. R., & Westenskow, P. D. (2024). Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-024-06531-9
Vancouver
Agostini H, Abreu F, Baumal CR, Chang DS, G Csaky K, Demetriades AM, et al. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes. Graefe's Archive for Clinical and Experimental Ophthalmology. 2024. doi:10.1007/s00417-024-06531-9
BibTeX
@article{Agostini2024,
author = {Agostini, Hansjürgen and Abreu, Francis and Baumal, Caroline R and Chang, Dolly S and G Csaky, Karl and Demetriades, Anna M and Kodjikian, Laurent and Lim, Jennifer I and Margaron, Philippe and Monés, Jordi M and Peto, Tunde and Ricci, Federico and Rüth, Matthias and Singh, Rishi P and Stoilov, Ivaylo and Swaminathan, Balakumar and Willis, Jeffrey R and Westenskow, Peter D},
title = {Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes},
journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
year = {2024},
doi = {10.1007/s00417-024-06531-9}
}
EUVIMED